In Brief: ChemTrak
This article was originally published in The Gray Sheet
Executive Summary
ChemTrak: Reacquires from Astra Merck exclusive U.S. marketing rights to its Hp Chek rapid whole blood H. pylori test. Astra Merck, which will pay ChemTrak $2.4 mil. to return the rights, retains an option to obtain non-exclusive distribution rights in the future. Astra Merck, which offers its Prilosec (omeprazole) drug for ulcer treatment, notes that "many more prescriptions for Prilosec are written to treat gastroesophageal reflux disease," and says it has decided to "focus on the core business." The test gained 510(k) clearance in June 1996 ("The Gray Sheet" July 8, 1996, In Brief)...
You may also be interested in...
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.